Humacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implant

Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks to boost sales of the device, it’s making sweeping cuts to keep up. Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks to boost sales of the device, it’s making sweeping cuts to keep up. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene…

Source: FierceBiotech